Legal status · Canada
Is FGF21 legal in Canada?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. FGF21 is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
FGF21 in Canada at a glance
| Classification | Investigational, not approved |
|---|---|
| Health Canada approval status | Not approved by Health Canada; investigational |
| Human studies cited | 4 of 10 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the FGF21 profile, checked against Health Canada, Health Products and Food Branch (Health Canada) listings at the reviewed date.
What this means
- 01
FGF21 is being studied in registered clinical trials but has not received Health Canada marketing approval in Canada.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What FGF21 is
A liver hormone released by fasting, sugar and protein restriction that signals through beta-klotho. Engineered analogues improved liver fibrosis in phase 2b MASH trials of 222 and 128 people; lifespan extension exists only in transgenic mice.
FGF21 is an endocrine fibroblast growth factor made mainly by the liver in response to fasting, ketogenic states, protein restriction, sugar intake and PPAR-alpha activation. Unlike the paracrine FGFs it lacks the heparin-binding domain that keeps them local, so it circulates, and it can act only on tissues that express its obligate co-receptor beta-klotho, principally fat, liver and parts of the brain.
Mechanism: Established in mice: fasting induces hepatic FGF21 through PPAR-alpha; FGF21 induces PGC-1alpha, drives fatty acid oxidation and ketogenesis, improves insulin sensitivity, suppresses growth hormone action, and causes bone loss. FGF21 signals through FGFR1c (and FGFR3c) only in the presence of beta-klotho, which is what restricts its action to fat, liver and specific brain regions.
Regulatory history: Not FDA-approved. Native FGF21 is not a drug. No FGF21 analogue (efruxifermin, pegozafermin, efimosfermin) had a Drugs@FDA record on 11 September 2026; efruxifermin and pegozafermin are in phase 3.
How Health Canada treats this kind of product
Authorises drugs for sale through a Notice of Compliance and Drug Identification Number. A compound that is not authorised for sale cannot lawfully be sold for human use, and personal importation of prescription drugs is limited.
The classification above is the The Longevity Archive reading of Health Canada, Health Products and Food Branch listings for FGF21 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
FGF21 in other countries
Frequently asked questions
Is FGF21 legal in Canada?
No. FGF21 is not approved for any medical use in Canada; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Can I buy FGF21 in Canada?
No approved product exists to buy. In Canada FGF21 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is FGF21 Health Canada approved?
No. In Canada FGF21 is classified as "Investigational, not approved", which is not a Health Canada marketing approval. For comparison, the US FDA status is: Not FDA-approved. Native FGF21 is not a drug. No FGF21 analogue (efruxifermin, pegozafermin, efimosfermin) had a Drugs@FDA record on 11 September 2026; efruxifermin and pegozafermin are in phase 3.. On the evidence, 4 human studies are cited on its profile.
Related compounds in Canada
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for FGF21 live on its compound profile.
FGF21 profileThis page is general information about the regulatory status of FGF21 in Canada, current as of Sep 2026. It is not legal advice, and classifications change; check Health Canada, Health Products and Food Branch directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.